A detailed history of Nuveen Asset Management, LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 796,902 shares of RXRX stock, worth $5.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
796,902
Previous 556,903 43.1%
Holding current value
$5.83 Million
Previous $5.49 Million 44.69%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$9.13 - $15.52 $2.19 Million - $3.72 Million
239,999 Added 43.1%
796,902 $7.95 Million
Q4 2023

Feb 14, 2024

SELL
$5.09 - $10.79 $2.19 Million - $4.64 Million
-430,436 Reduced 43.6%
556,903 $5.49 Million
Q3 2023

Nov 14, 2023

SELL
$6.59 - $15.86 $911,436 - $2.19 Million
-138,306 Reduced 12.29%
987,339 $7.55 Million
Q2 2023

Aug 14, 2023

BUY
$4.56 - $9.94 $456,273 - $994,596
100,060 Added 9.76%
1,125,645 $8.41 Million
Q1 2023

May 15, 2023

SELL
$6.42 - $9.64 $782,238 - $1.17 Million
-121,844 Reduced 10.62%
1,025,585 $6.84 Million
Q4 2022

Feb 14, 2023

BUY
$7.16 - $12.7 $2.15 Million - $3.81 Million
300,292 Added 35.45%
1,147,429 $8.85 Million
Q3 2022

Nov 14, 2022

BUY
$7.83 - $13.6 $2.18 Million - $3.79 Million
278,555 Added 48.99%
847,137 $9.01 Million
Q2 2022

Aug 15, 2022

BUY
$5.04 - $9.26 $650,774 - $1.2 Million
129,122 Added 29.38%
568,582 $4.63 Million
Q1 2022

May 16, 2022

BUY
$6.16 - $18.03 $426,604 - $1.25 Million
69,254 Added 18.71%
439,460 $2.91 Million
Q4 2021

Feb 14, 2022

BUY
$16.14 - $21.86 $4.49 Million - $6.08 Million
278,323 Added 302.91%
370,206 $6.68 Million
Q3 2021

Nov 12, 2021

BUY
$19.03 - $41.33 $250,301 - $543,613
13,153 Added 16.71%
91,883 $2.46 Million
Q2 2021

Aug 16, 2021

BUY
$18.0 - $37.42 $1.42 Million - $2.95 Million
78,730 New
78,730 $2.87 Million

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.32B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.